These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1130 related articles for article (PubMed ID: 30407504)

  • 1. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy.
    Chen YP; Wang YQ; Lv JW; Li YQ; Chua MLK; Le QT; Lee N; Colevas AD; Seiwert T; Hayes DN; Riaz N; Vermorken JB; O'Sullivan B; He QM; Yang XJ; Tang LL; Mao YP; Sun Y; Liu N; Ma J
    Ann Oncol; 2019 Jan; 30(1):68-75. PubMed ID: 30407504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment.
    Li ZX; Zheng ZQ; Wei ZH; Zhang LL; Li F; Lin L; Liu RQ; Huang XD; Lv JW; Chen FP; He XJ; Guan JL; Kou J; Ma J; Zhou GQ; Sun Y
    Theranostics; 2019; 9(25):7648-7665. PubMed ID: 31695792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA-methylome-derived epigenetic fingerprint as an immunophenotype indicator of durable clinical immunotherapeutic benefits in head and neck squamous cell carcinoma.
    Li R; Wen X; Lv RX; Ren XY; Cheng BL; Wang YK; Chen RZ; Hu W; Tang XR
    Cell Oncol (Dordr); 2024 Aug; 47(4):1129-1148. PubMed ID: 38315286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Chromatin Regulator-related Molecular Subtypes and a Signature to Predict Prognosis and Immunotherapeutic Response in Head and Neck Squamous Cell Carcinoma.
    Huang J; Xu Z; Wang Z; Zhou C; Shen Y
    Curr Cancer Drug Targets; 2024; 24(8):804-819. PubMed ID: 38310463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma.
    Mito I; Takahashi H; Kawabata-Iwakawa R; Ida S; Tada H; Chikamatsu K
    Sci Rep; 2021 Aug; 11(1):16134. PubMed ID: 34373557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptome analysis reveals the link between lncRNA-mRNA co-expression network and tumor immune microenvironment and overall survival in head and neck squamous cell carcinoma.
    Zhong Z; Hong M; Chen X; Xi Y; Xu Y; Kong D; Deng J; Li Y; Hu R; Sun C; Liang J
    BMC Med Genomics; 2020 Mar; 13(1):57. PubMed ID: 32228580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels the molecular feature of M2 macrophages of head and neck squamous cell carcinoma.
    Wu S; Lv X; Wei H; Wu J; Liu S; Li X; Song J; Zou C; Ai Y
    J Cell Mol Med; 2024 Mar; 28(5):e18083. PubMed ID: 38393307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification immunophenotyping of lung adenocarcinomas based on the tumor microenvironment.
    Tan Q; Huang Y; Deng K; Lu M; Wang L; Rong Z; Zhao W; Li S; Xu Z; Fan L; Li K; Li Z
    J Cell Biochem; 2020 Nov; 121(11):4569-4579. PubMed ID: 32030808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NT5E upregulation in head and neck squamous cell carcinoma: A novel biomarker on cancer-associated fibroblasts for predicting immunosuppressive tumor microenvironment.
    Chen XM; Liu YY; Tao BY; Xue XM; Zhang XX; Wang LL; Zhong H; Zhang J; Yang SM; Jiang QQ
    Front Immunol; 2022; 13():975847. PubMed ID: 36091055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of a novel ferroptosis-related gene signature for predicting prognosis and immune microenvironment in head and neck squamous cell carcinoma.
    He F; Chen Z; Deng W; Zhan T; Huang X; Zheng Y; Yang H
    Int Immunopharmacol; 2021 Sep; 98():107789. PubMed ID: 34130150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOXD1 expression in head and neck squamous carcinoma: a study based on TCGA, GEO and meta-analysis.
    Huang J; Liang B; Wang T
    Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34269372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune microenvironment of the gene signature reflecting the standardised uptake value on
    Han S; Oh JS; Kim JS
    Ann Nucl Med; 2021 Jan; 35(1):65-75. PubMed ID: 33044632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment and validation of immune microenvironmental gene signatures for predicting prognosis in patients with head and neck squamous cell carcinoma.
    Wang J; Tian Y; Zhu G; Li Z; Wu Z; Wei G; Zhuang L; Li Z; Chen X; Zhang X; Zheng J; Cai G
    Int Immunopharmacol; 2021 Aug; 97():107817. PubMed ID: 34091115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profiles of immune cell infiltration in head and neck squamous carcinoma.
    Liang B; Tao Y; Wang T
    Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32095823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features.
    Sia D; Jiao Y; Martinez-Quetglas I; Kuchuk O; Villacorta-Martin C; Castro de Moura M; Putra J; Camprecios G; Bassaganyas L; Akers N; Losic B; Waxman S; Thung SN; Mazzaferro V; Esteller M; Friedman SL; Schwartz M; Villanueva A; Llovet JM
    Gastroenterology; 2017 Sep; 153(3):812-826. PubMed ID: 28624577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The viral expression and immune status in human cancers and insights into novel biomarkers of immunotherapy.
    Chen S; Lai H; Zhao J; Chen B; Li Y; Li Y; Li Q; Zheng Q; Huang S; Zhu X
    BMC Cancer; 2021 Nov; 21(1):1183. PubMed ID: 34740324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of the Immune Cell Infiltration Landscape in Head and Neck Squamous Cell Carcinoma (HNSC) for the Exploration of Immunotherapy and Prognosis.
    Huang C; Liu J
    Genet Res (Camb); 2022; 2022():6880760. PubMed ID: 36636556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of immune response biomarkers (PD‑L1, p16, CD3+ and CD8+ TILs) in recurrent head and neck squamous cell carcinoma within previously irradiated areas.
    Pflumio C; Thomas J; Salleron J; Faivre JC; Borel C; Dolivet G; Sastre-Garau X; Geoffrois L
    Oncol Rep; 2021 Mar; 45(3):1273-1283. PubMed ID: 33432367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
    Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
    Front Immunol; 2021; 12():690056. PubMed ID: 34335594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A TP53 mutation model for the prediction of prognosis and therapeutic responses in head and neck squamous cell carcinoma.
    Shi C; Liu S; Tian X; Wang X; Gao P
    BMC Cancer; 2021 Sep; 21(1):1035. PubMed ID: 34530752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.